Cost-effectiveness of tezepelumab in Canada for severe asthma ...
Taylor & Francis, 2023
academicJournal
Zugriff:
To assess the cost-effectiveness of tezepelumab as add-on maintenance therapy compared with standard of care (SoC) for the treatment of patients with severe asthma in Canada. A cost utility analysis was conducted using a Markov cohort model with five health states (“controlled asthma”, “uncontrolled asthma”, “previously controlled asthma with exacerbation”, “previously uncontrolled asthma with exacerbation”, and “death”). Tezepelumab plus SoC was compared to SoC (high-dose inhaled corticosteroids plus long-acting beta agonist) using efficacy estimates derived from the NAVIGATOR (NCT03347279) and SOURCE (NCT03406078) trials. The model included the costs of therapy, administration, resource use for disease management, and adverse events. Utility estimates were calculated using a mixed-effects regression analysis of the NAVIGATOR and SOURCE trials. A Canadian public payer perspective was used with a 50-year time horizon, a 1.5% annual discount rate, and the base case analysis was conducted probabilistically. A ...
Titel: |
Cost-effectiveness of tezepelumab in Canada for severe asthma ...
|
---|---|
Autor/in / Beteiligte Person: | Habash, Mara ; Guiang, Hannah ; Mayers, Irvin ; Quinton, Anna ; Vuong, Vivian ; Dineen, Aidan ; Singh, Sumeet ; Gibson, Danny ; Turner, Adrian P. |
Link: |
|
Veröffentlichung: | Taylor & Francis, 2023 |
Medientyp: | academicJournal |
DOI: | 10.6084/m9.figshare.23642802.v2 |
Schlagwort: |
|
Sonstiges: |
|